PARP Inhibitor Drugs Could Also Treat ALS


A class of cancer drugs in development called PARP inhibitors could be useful for treating and preventing brain disorders, including amyotrophic lateral sclerosis (ALS), and some forms of frontotemporal degeneration (FTD), a new study from the University of Pennsylvania indicates.

The protein TDP-43, when mistakenly outside the nucleus, forms clumps in brain cells that are affected in ALS and FTD. When out-of-place TDP-43 binds to another molecule, PAR, it amasses in cellular structures called stress granules. While this initial accumulation does not cause imminent harm to a cell, after a prolonged period, TDP-43 changes into structures that are observed in brain diseases.

Now, a team led by Nancy Bonini, Ph.D., a professor of Biology, and James Shorter, Ph.D., a professor of Biochemistry and Biophysics, have found that PARP inhibitors, which stop PAR a (poly ADP-ribose) from being generated, reduced the amount of harmful TDP-43 structures in cells under stress.

Limited Treatment Options

Diseases like ALS and FTD-TDP-43 are devastating both for the patient and family and there are limited treatment options.

“What excited me about pursuing this pathway was the promise of small molecules that attack the disease process of TDP-43. When I tested them on cultured cells, I found they could alleviate the buildup of TDP-43 that mirrors the abnormal protein clumps we see in disease,”

said lead author Leeanne McGurk, Ph.D., a research associate in Bonini’s lab.

In test-tube experiments, the team found that TDP-43 can change from a soluble form to a condensed liquid form by interacting with other TDP-43 molecules and macromolecules like PAR.

“The liquid form of TDP-43 is representive of a stress granule and is likely beneficial,”

Shorter said; however, he noted that if these liquid forms of TDP-43 solidify with time they can be difficult to remove.

PAR Promotes TDP-43 Phase Separation

This study’s promise is that a drug in development as a cancer therapeutic could be used to prevent the formation of harmful TDP-43 clumps in cells.

“The PARP inhibitors we tested that antagonized the cytoplasmic accumulation of TDP-43 may one day be optimized as valuable therapeutics for brain diseases,”

said coauthor Edward Gomes, MS, a research specialist Shorter’s lab.

While this work is still being done in the lab, the team’s findings provide the next step for neurologists looking for new ways to fight neurodegenerative disorders.

“Given the lack of treatment options, we are excited by these experiments that help elucidate molecular events that could lead to new therapeutics,”

said Bonini.

A hyper-phosphorylated, ubiquitinated and cleaved form of TDP-43 — known as pathologic TDP43 — is the major disease protein in ubiquitin-positive, tau-, and alpha-synuclein-negative frontotemporal dementia (FTLD-TDP, previously referred to as FTLD-U) and in amyotrophic lateral sclerosis (ALS).

Elevated levels of the TDP-43 protein have also been identified in individuals diagnosed with chronic traumatic encephalopathy, a condition that often mimics ALS and that has been associated with athletes who have experienced multiple concussions and other types of head injury. Abnormalities of TDP-43 also occur in an important subset of Alzheimer’s disease patients, correlating with clinical and neuropathologic features indexes.

Leeanne McGurk, Edward Gomes, Lin Guo, Jelena Mojsilovic-Petrovic, Van Tran, Robert G. Kalb, James Shorter, Nancy M. Bonini
Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization
Molecular Cell

Last Updated on November 10, 2022